Menu Search
Equities

Heron Therapeutics Inc

AXD2:STU

Heron Therapeutics Inc

Actions
  • Price (EUR)1.15
  • Today's Change-0.35 / -23.33%
  • Shares traded10.00
  • 1 Year change+127.72%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Heron Therapeutics Inc grew revenues 17.99% from 107.67m to 127.04m while net income improved from a loss of 182.02m to a smaller loss of 110.56m.
Gross margin65.49%
Net profit margin-35.29%
Operating margin-32.63%
Return on assets-22.95%
Return on equity--
Return on investment-38.15%
More ▼

Cash flow in USDView more

In 2023, Heron Therapeutics Inc increased its cash reserves by 86.65%, or 13.31m. Cash Flow from Financing totalled 54.11m or 42.59% of revenues. In addition the company used 58.79m for operations while cash from investing totalled 18.00m.
Cash flow per share-0.3025
Price/Cash flow per share--
Book value per share-0.2503
Tangible book value per share-0.2503
More ▼

Balance sheet in USDView more

Heron Therapeutics Inc has a Debt to Total Capital ratio of 133.98%.
Current ratio2.38
Quick ratio1.85
Total debt/total equity--
Total debt/total capital1.34
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.